CMPS

Compass Pathways
CMPS
Market cap $343M

3.67 USD

-0.05

1.34%

At close Jul 11, 4:00 PM EDT

After hours

3.69

+0.02

0.54%

1 day

-1.34%

5 days

12.58%

1 month

-20.04%

3 months

28.77%

6 months

8.90%

Year to date

-11.57%

1 year

-49.17%

5 years

-87.34%

10 years

-87.34%

About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Employees: 166

Healthcare Medical Care Facilities

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

60% more call options, than puts

Call options by funds: $1.56M | Put options by funds: $974K

44% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 27

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

27% more capital invested

Capital invested by funds: $117M [Q4 2024] → $148M (+$31.4M) [Q1 2025]

10.78% more ownership

Funds ownership: 45.23% [Q4 2024] → 56.01% (+10.78%) [Q1 2025]

4% more funds holding

Funds holding: 131 [Q4 2024] → 136 (+5) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

63%

upside

Avg. target

$21

472%

upside

High target

$45

1,126%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Evercore ISI Group Josh Schimmer	63%upside $6	In-Line Downgraded	23 Jun 2025
Cantor Fitzgerald Josh Schimmer	227%upside $12	Overweight Assumed	27 May 2025
HC Wainwright & Co. Patrick Trucchio	1,126%upside $45	Buy Reiterated	12 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about CMPS published over the past 30 days

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright at 8:00 am ET on July 14th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the.

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

Zacks Investment Research

COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why

Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360

I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billion by 2035.

Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360

Proactive Investors

Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint

Compass Pathways (NASDAQ:CMPS) has reported positive results from its Phase 3 trial of its synthetic formulation of psilocybin, COMP360, in patients with treatment-resistant depression (TRD), with the trial meeting its primary endpoint. A single 25 mg dose of COMP360 demonstrated a highly statistically significant and clinically meaningful reduction in depression symptom severity compared to placebo, with a mean difference of 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6.

Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Shares of Compass Pathways Plc plunged as much as 37% during pre-market trading on Monday after the company's experimental psilocybin treatment for a form of hard-to-treat depression produced results that, while technically successful, fell short of investor expectations.

Compass Pathways stock slip as psilocybin depression trial falls short of expectations

Compass Pathways' depression drug succeeds late-stage trial

Compass Pathways said on Monday its experimental psilocybin-based therapy helped significantly reduce symptoms of difficult-to-treat depression in a late-stage study.

Compass Pathways' depression drug succeeds late-stage trial

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint is the difference in change from baseline in the Montgomery.

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Proactive Investors

FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks

The Food and Drug Administration (FDA) may soon issue emergency use authorizations for psychedelic substances like psilocybin, proponents of psychedelic therapy believe, amid a shit in attitude towards psychedelic therapies under the Trump administration. Emergency use authorizations (EUAs) are considered a more likely near-term regulatory pathway for psychedelics such as psilocybin because, unlike full FDA approval, they require a lower standard of evidence, a report from health-oriented news website Stat published on Wednesday highlighted.

FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocks

Zacks Investment Research

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

See News Rankings

Charts implemented using Lightweight Charts™